Allogeneic cell therapy scales one qualified donor or cell source into banks, production campaigns, drug-product lots, and doses for many recipients. That leverage makes genealogy more important: one upstream finding can affect a wide downstream population, while every dose still requires exact identity, custody, condition, and release.
Seal connects donor eligibility, source material, collections, cell banks, engineering, passages, cultures, harvests, pools, formulation, fills, testing, cryostorage, distribution, allocation, administration, and post-use impact.
The product definition includes the biological source
The controlled product connects intended cell type, donor or source criteria, construct or edit, bank strategy, process, critical attributes, formulation, container, specifications, potency, stability, storage, indication, and regulatory state.
Versions distinguish research, engineering, clinical, PPQ, and commercial configurations. Approved applicability determines which banks and process versions can create a clinical or commercial dose.
Donor identity and privacy are separated deliberately
A coded donor identity supports manufacturing genealogy without exposing unnecessary personal information. Eligibility and screening decisions can be referenced from an authoritative clinical or donor system while Seal retains the approved manufacturing status, source event, consent restrictions where applicable, and identifiers needed for traceability.
Access to direct identifiers is restricted and audited. Operational labels and searches use controlled codes rather than patient-facing data.
Donor eligibility is a time-bound decision
Screening, testing, history, collection suitability, geography, timing, deferrals, follow-up, and responsible-person approval form an eligibility record. Pending, eligible, ineligible, incomplete, and exception states remain explicit.
Starting material can be quarantined and processed under approved conditions while final eligibility is pending, but every downstream object inherits the unresolved gate.
Collection and receipt preserve custody and condition
Collection center, procedure, kit and component lots, anticoagulant, timestamps, container identifiers, seal, quantity, cell count, temperature, courier, shipper, custody, and receipt inspection remain connected.
Expected and actual shipments are reconciled. Label discrepancy, temperature excursion, damage, delay, insufficient quantity, or missing donor evidence opens a controlled assessment before manufacturing use.
Cell banks create scalable biological lineage
Pre-master, master, working, intermediate, or production banks retain source, derivation, passages, population doublings, construct or edit, clonality where relevant, characterization, release, storage positions, vials, withdrawals, and remaining population.
Each bank template defines permitted descendants and use. A vial withdrawal is an accountable physical event, not a quantity decrement in generic inventory.
Engineering and editing retain input-to-cell evidence
Vector transduction, electroporation, nuclease, guide RNA, donor template, selection, activation, or other manipulation connects reagent and vector lots, cell state, equipment, parameters, timing, samples, efficiency, off-target or residual testing, and acceptance.
The edited or engineered cell population becomes a new material state with source lineage and hold. Reprocessing and repeat manipulation require approved branches.
Expansion controls passages, time, and population
Seed train, vessels, media, cytokines, feeds, supplements, cell density, viability, phenotype, morphology, population doublings, passages, harvest criteria, automation, samples, and decisions are recorded through expansion.
Split and pool events preserve source and destination quantities. The system enforces maximum passage or expansion age and exposes approaching hold or scheduling constraints.
Facility, suite, closed-system configuration, equipment, incubators, single-use assemblies, materials, people, cleaning, line clearance, and temporal segregation define the campaign state.
Concurrent products or lineages remain physically and electronically separated. Shared incubators and cryogenic storage retain container, position, access, alarm, and excursion history.
Harvest, formulation, and fill preserve dose math
Harvested cells, washes, selection, concentration, pooling, formulation, fill, cryoprotectant, target dose, fill volume, overage, samples, rejects, and yields form controlled transformations.
Total viable cells, viable cell concentration, recovery, container count, retained samples, and rejected units reconcile from pool to fill. A dose claim retains the actual formulation and count evidence that supports it.
Quality testing remains stage- and population-specific
Identity, viability, cell count, purity, phenotype, potency, sterility, mycoplasma, endotoxin, replication-
Samples and methods retain physical lineage, timing, instrument, critical reagents, calculations, specifications, result status, and review. A bank-
Potency links mechanism, assay system, and dose decision
Potency assays can depend on cells, target cells, reagents, incubation, plate maps, imaging or cytometry, instruments, controls, reference standards, calculation, suitability, and method version. Seal preserves those dependencies with the result.
Method drift and critical reagent changes can be assessed against affected batches and historical cohorts without stripping away manufacturing context.
Chain of identity changes shape after banking
Autologous manufacturing binds one patient to one batch. Allogeneic manufacturing binds a donor-derived lineage to many doses, then allocates individual containers to recipients. Seal separates donor lineage identity, product and lot identity, and recipient allocation identity.
Verification at allocation, pick, ship, receipt, and administration prevents a dose from losing either its manufacturing source or its intended recipient.
Cryostorage is active manufacturing state
Freezer, tank, cane, rack, box, position, temperature, alarm, access, movement, freeze profile, thaw, and exposure remain connected to each bank vial, intermediate, dose, and sample. Inventory counts reconcile physical positions and reservations.
Excursions identify the exact population in the affected zone and interval, including doses already shipped or administered.
Release can occur at bank, batch, lot, and dose levels
Bank disposition, production-batch progression, drug-product lot release, and individual-
Long-duration tests and conditional states remain explicit. The decision freezes evidence available at the time and preserves required follow-up.
Allocation and distribution protect scarce inventory
Clinical or commercial orders identify site, recipient code, dose, timing, product eligibility, reservation, shipper, route, and contingency. Allocation considers released inventory, location, expiry, shipping qualification, center readiness, and replacement margin.
Pick and pack verify exact container, label, shipper configuration, conditioning, logger, seal, documents, custody, and departure. Receipt and administration close the handoff.
A source finding can trace forward to recipients
A donor, bank, vector, reagent, equipment, assay, freezer, process, or supplier concern traverses campaigns, pools, lots, doses, shipments, clinical sites, and recipients. Scope reflects the actual genealogy rather than every product of the same name.
Notification and field action remain governed by quality, clinical, safety, and regulatory roles. Privacy boundaries do not prevent authorized impact tracing.
Comparability preserves generations and cohorts
Donor source, bank generation, clone, edit, vector, process, vessel, scale, medium, raw material, site, method, formulation, container, or cryopreservation changes create explicit populations.
Comparability evidence connects changes to samples, methods, results, release, stability, clinical lots, and regulatory decisions. Historical genealogy remains immutable.
Prove one donor-to-recipient branch
The first implementation should follow one coded donor and collection through eligibility, receipt, engineering, master and working bank, production vial withdrawal, expansion, harvest, formulation, fill, testing, lot and dose release, cryostorage, allocation, shipment, and administration.
Include pending donor evidence, collection excursion, editing-efficiency failure, passage-limit branch, pool quantity discrepancy, invalid potency run, conditional sterility state, freezer-zone excursion, dose replacement, and post-administration source alert. The model is ready when one source can trace to every recipient and one dose can reconstruct its complete source.
